TCM
NVO

Triumph Capital Management’s Novo Nordisk NVO Stock Holding History

Triumph Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5K Buy
365
+167
+84% +$7.17K ﹤0.01% 983
2026
Q1 		$7.51K Sell
198
-80
-29% -$3.79K ﹤0.01% 1192
2025
Q4 		$14.1K Buy
+278
New +$14.2K ﹤0.01% 967

Other funds holding NVO

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
ONB
Old National Bancorp Evansville, Indiana $5.02B AUM 25.65% 1-Year Est. Return

Triumph Capital Management's NVO Position: Q2 2026 in Review

Triumph Capital Management increased its Novo Nordisk (NVO) stake by 84% in Q2 2026, buying an estimated $7.17K and bringing the position to 365 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #983.

Triumph Capital Management first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. 314 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Triumph Capital Management held 365 shares of Novo Nordisk worth $17.5K as of Q2 2026.
  • Triumph Capital Management bought 167 Novo Nordisk shares in Q2 2026, an estimated $7.17K.
  • Novo Nordisk made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #983 holding.
  • Triumph Capital Management first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • 314 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.